Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Uloric Cleared For Gout Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

Labeling for the xanthine oxidase inhibitor includes a Warning on cardiovascular safety, a concern of FDA’s.

You may also be interested in...

Takeda’s Uloric: CV Mortality Signal Leads US FDA To Ponder Regulatory Options

Advisory committee will discuss whether CARES postmarketing trial showing 34% increased risk of cardiovascular death for febuxostat warrants market withdrawal, use restrictions, or new labeling for the gout drug.

Savient Suggests More Restrictive REMS Plan For Pegloticase In BLA Amendment

PDUFA date shifts to July 30; FDA to reschedule advisory committee.

PPI Market Snapshot: Kapidex Joins The Party Fashionably Late

Undeterred by a crammed proton pump inhibitor market already filled with established brand drugs, low-cost generics and over-the-counter alternatives, Takeda is moving ahead with the launch of a new PPI, Kapidex (dexlansoprazole)

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts